Cargando…

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort

Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in NAPOLI-1 trial, in which Asian patients experienced more hematological toxicity and subsequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yung-Yeh, Chiang, Nai-Jung, Tsai, Hui-Jen, Yen, Chia-Jui, Shan, Yan‐Shen, Chen, Li‐Tzong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198559/
https://www.ncbi.nlm.nih.gov/pubmed/32366911
http://dx.doi.org/10.1038/s41598-020-64421-6
_version_ 1783529012260241408
author Su, Yung-Yeh
Chiang, Nai-Jung
Tsai, Hui-Jen
Yen, Chia-Jui
Shan, Yan‐Shen
Chen, Li‐Tzong
author_facet Su, Yung-Yeh
Chiang, Nai-Jung
Tsai, Hui-Jen
Yen, Chia-Jui
Shan, Yan‐Shen
Chen, Li‐Tzong
author_sort Su, Yung-Yeh
collection PubMed
description Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in NAPOLI-1 trial, in which Asian patients experienced more hematological toxicity and subsequent dose modification. A retrospective chart review to investigate the administration pattern, therapeutic efficacy and safety profile of nal-IRI + 5-FU/LV in 44 consecutive patients with gemcitabine-refractory advanced PDAC treated between December 2016 and December 2018 in National Cheng Kung University Hospital, Taiwan. Most of them had metastatic diseases (88.6%), one-line of prior treatment (72.7%), ECOG PS 0-1 (72.7%) and starting dose of nal-IRI at 60 mg/m(2) (≈52 mg/m(2) irinotecan free-base) in 65.9%. The overall response rate was 9.1%. The median OS was 6.6 months for the entire cohort, and 7.8 and 2.7 months for patients of ECOG PS 0-1 and>2, respectively. The median OS of ECOG PS 0-1 patients with nal-IRI starting doses at 80 mg/m(2) (≈70 mg/m(2) irinotecan free-base, n = 13) and 60 mg/m(2) (n = 19) were 7.5 and 8.4 months, respectively. Thirty-four percent of patients experienced manageable grade 3-4 hematological toxicity. Our results confirm the clinical benefit of nal-IRI + 5-FU/LV for patients of gemcitabine-refractory advanced PDAC with good performance status in a real-world setting.
format Online
Article
Text
id pubmed-7198559
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71985592020-05-08 The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort Su, Yung-Yeh Chiang, Nai-Jung Tsai, Hui-Jen Yen, Chia-Jui Shan, Yan‐Shen Chen, Li‐Tzong Sci Rep Article Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in NAPOLI-1 trial, in which Asian patients experienced more hematological toxicity and subsequent dose modification. A retrospective chart review to investigate the administration pattern, therapeutic efficacy and safety profile of nal-IRI + 5-FU/LV in 44 consecutive patients with gemcitabine-refractory advanced PDAC treated between December 2016 and December 2018 in National Cheng Kung University Hospital, Taiwan. Most of them had metastatic diseases (88.6%), one-line of prior treatment (72.7%), ECOG PS 0-1 (72.7%) and starting dose of nal-IRI at 60 mg/m(2) (≈52 mg/m(2) irinotecan free-base) in 65.9%. The overall response rate was 9.1%. The median OS was 6.6 months for the entire cohort, and 7.8 and 2.7 months for patients of ECOG PS 0-1 and>2, respectively. The median OS of ECOG PS 0-1 patients with nal-IRI starting doses at 80 mg/m(2) (≈70 mg/m(2) irinotecan free-base, n = 13) and 60 mg/m(2) (n = 19) were 7.5 and 8.4 months, respectively. Thirty-four percent of patients experienced manageable grade 3-4 hematological toxicity. Our results confirm the clinical benefit of nal-IRI + 5-FU/LV for patients of gemcitabine-refractory advanced PDAC with good performance status in a real-world setting. Nature Publishing Group UK 2020-05-04 /pmc/articles/PMC7198559/ /pubmed/32366911 http://dx.doi.org/10.1038/s41598-020-64421-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Su, Yung-Yeh
Chiang, Nai-Jung
Tsai, Hui-Jen
Yen, Chia-Jui
Shan, Yan‐Shen
Chen, Li‐Tzong
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
title The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
title_full The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
title_fullStr The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
title_full_unstemmed The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
title_short The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
title_sort impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a taiwanese cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198559/
https://www.ncbi.nlm.nih.gov/pubmed/32366911
http://dx.doi.org/10.1038/s41598-020-64421-6
work_keys_str_mv AT suyungyeh theimpactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT chiangnaijung theimpactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT tsaihuijen theimpactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT yenchiajui theimpactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT shanyanshen theimpactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT chenlitzong theimpactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT suyungyeh impactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT chiangnaijung impactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT tsaihuijen impactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT yenchiajui impactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT shanyanshen impactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort
AT chenlitzong impactofliposomalirinotecanonthetreatmentofadvancedpancreaticadenocarcinomarealworldexperienceinataiwanesecohort